ReviewHormones & cancer2010
Microenvironment and pathogenesis of epithelial ovarian cancer.
Review in Hormones & cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 72 citations in OpenAlex.
- Aptamer-Coated PLGA Nanoparticles Selectively Internalize into Epithelial Ovarian Cancer Cells In Vitro and In Vivo.Biomolecules · 2025Article
- Sensitive and Cost-Effective Tools in the Detection of Ovarian Cancer Biomarkers.Analytical science advances · 2024Article
- Banning asbestos in talcum powder: Time for action in India.Dialogues in health · 2023Article
- Do Aging and Parity Affect VEGF-A/VEGFR Content and Signaling in the Ovary?-A Mouse Model Study.International journal of molecular sciences · 2023Article
- Obesity modulates the cellular and molecular microenvironment in the peritoneal cavity: implication for ovarian cancer risk.Frontiers in immunology · 2023Article
- The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis.Antioxidants (Basel, Switzerland) · 2022Review
- Expression status and prognostic significance of mitochondrial dynamics OPA3 in human ovarian cancer.Aging · 2022Article
- PAX8 as a Potential Target for Ovarian Cancer: What We Know so Far.OncoTargets and therapy · 2022Review
- Ovarian cancer health politics in Romania and Germany: A comparative study.Experimental and therapeutic medicine · 2021Article
- Review
- Asbestos Exposure and Ovarian Cancer - a Gynaecological Occupational Disease. Background, Mandatory Notification, Practical Approach.Geburtshilfe und Frauenheilkunde · 2021Article
- An unprecedented endocrine target for ovarian cancer: inhibiting 17β-HSD7 supresses cancer cell proliferation and arrests G2/M cycle.American journal of cancer research · 2021Article
- Paired-like homeodomain 2B contributes to tumour progression and anti-autophagy in human lung cancer.American journal of cancer research · 2021Article
- Review
- Serum vitamin D deficiency and risk of epithelial ovarian cancer in Lagos, Nigeria.Ecancermedicalscience · 2020Article
- The Potential Role of iNOS in Ovarian Cancer Progression and Chemoresistance.International journal of molecular sciences · 2019Review
- Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer.Journal of experimental & clinical cancer research : CR · 2019Article
- Alteration of microRNA profiling in sphere-cultured ovarian carcinoma cells.Oncology letters · 2018Article
- The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.International journal of molecular sciences · 2018Review
- Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.Cancer research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Multiple genetic alterations play a role in the pathogenesis of ovarian cancer. Although many key proteins and pathways involved in ovarian carcinogenesis and metastasis have been discovered, knowledge of the early steps leading to malignancy remains poorly understood. This poor understanding stems from lack of data from early-stage cancers and absence of a well-established premalignant state universal to all ovarian cancer subtypes. Existing evidence suggests that ovarian cancers develop either through a stepwise mutation process (low-grade pathway), through genetic instability resulting in hastened metastasis (high-grade pathway), or more recently through what has been described as the "'fimbrial-ovarian' serous neoplasia theory." In this latter model, ovarian serous cancers evolve from premalignant lesions in the distal fallopian tube called tubal intraepithelial carcinoma. In this manuscript, we review key genetic and molecular changes that occur in cancer cell progression and suggest a model of ovarian cancer pathogenesis involving both tumor cell mutations and microenvironmental factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.